A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition

BACKGROUND: The initial use of BRAF targeted therapeutics in clinical trials has demonstrated encouraging responses in melanoma patients, although a rise in drug-resistant cells capable of advancing malignant disease has been described. The current study uses BRAF(V600E )expressing WM793 melanoma ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, R Matthew, Higgins, Paul J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180434/
https://www.ncbi.nlm.nih.gov/pubmed/21917148
http://dx.doi.org/10.1186/1476-4598-10-114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180434/
https://www.ncbi.nlm.nih.gov/pubmed/21917148
http://dx.doi.org/10.1186/1476-4598-10-114

Ejemplares similares